Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers

Cardio-oncology is a recently established discipline that focuses on the management of patients with cancer who are at risk for developing cardiovascular complications as a result of their underlying oncologic treatment. In metastatic colorectal cancer (mCRC) and metastatic renal cell carcinoma (mRCC), vascular endothelial growth factor inhibitor (VEGF-i) therapy is commonly used to improve overall survival. Although these novel anticancer drugs may lead to the development of cardiotoxicity, whether early detection of cardiac dysfunction using serial echocardiography could potentially prevent the development of heart failure in this patient population requires further study.

Source: Journal of the American Society of Echocardiography - November 17, 2018 Category: Cardiology Authors: Lara F. Nhola, Sahar S. Abdelmoneim, Hector R. Villarraga, Manish Kohli, Axel Grothey, Kimberly-Ann Bordun, Matthew Cheung, Ryan Best, David Cheung, Runqing Huang, Sergio Barros-Gomes, Marshall Pitz, Pawan K. Singal, Davinder S. Jassal, Sharon L. Mulvagh Source Type: research